Literature DB >> 2420429

Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations.

K G Warren, I Catz, V M Jeffrey, D J Carroll.   

Abstract

Clinical exacerbations of multiple sclerosis (MS) are characterized by elevated levels of cerebrospinal fluid (CSF) myelin basic protein (MBP). The purposes of this study were to determine whether anti-MBP antibodies are present in increased titer in CSF of MS patients with exacerbations, and whether they can be suppressed by the administration of immunosuppressive dosages of methylprednisolone (MP). A solid phase radio-immunoassay (RIA) was used to detect free and total anti-MBP antibodies before and after acid hydrolysis of CSF. In MS exacerbations, the majority of elevated anti-MBP is in the free form. With the exception of subacute sclerosing panencephalitis (SSPE) and some cases of post infectious encephalomyelitis, anti-MBP antibodies are not present in either MS patients in remission or in non-MS controls. Anti-MBP levels remained elevated over a 10 day period when patients are managed by bed rest only or when treated with intravenous (IV) ACTH. IV administration of MP in "high" (160 mg/day) or "mega" (2 g/day) dosages produces a highly significant reduction of both MBP (p less than 0.01) and anti-MBP (p less than 0.001) levels. Total intrathecal IgG synthesis is also significantly suppressed by IV-MP but not by ACTH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2420429     DOI: 10.1017/s0317167100035757

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

1.  The need for a new strategy for the treatment of multiple sclerosis.

Authors:  A N Davison
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

2.  High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

Authors:  D H Miller; A J Thompson; S P Morrissey; D G MacManus; S G Moore; B E Kendall; I F Moseley; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

3.  Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.

Authors:  R D Medenica; S Mukerjee; K Alonso; G Lazovic; T Huschart
Journal:  J Clin Apher       Date:  1994       Impact factor: 2.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.